The FDA granted Prime Medicine orphan status for its treatment of glycogen storage disease type 1B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRME:
- Stellantis cuts 2024 targets, TPG acquires AT&T’s DirecTV stake: Morning Buzz
- Prime Medicine prioritization, Bristol deal positive, says Morgan Stanley
- Prime Medicine pact with Bristol doesn’t change thesis, says Stifel
- Morning Movers: Stellantis skids following FY24 guidance cut
- Prime Medicine Strikes $3.5B Deal for T-Cell Therapy Advances